focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.175%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 64.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options to Directors

26 Jun 2018 16:24

RNS Number : 6584S
NetScientific PLC
26 June 2018
 

 

 

 ("NetScientific" or the "Company" or the "Group")

 

NetScientific plc

 

Grant of Options to Directors

 

London, UK - 26th June 2018 - NetScientific plc (AIM:NSCI) (the "Company"), the transatlantic healthcare IP commercialisation Group, today announced that on 21st June 2018, options over ordinary shares of 5p each were granted to its CEO François Martelet and CFO Ian Postlethwaite as detailed below (the "New Options").

 

Director

Number of Options Granted

Total Number of Options Held

Francois Martelet

300,000

1,059,020

Ian Postlethwaite

200,000

560,000

 

The New Options have an exercise price of 45.5 pence per share, being the average closing price for the ordinary shares over the five dealing days prior to the date on which the options were granted. The New Options vest three years from the date of grant.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

 Consilium Strategic Communications

Mary-Jane Elliott Jessica Hodgson /

Chris Welsh / Laura Thornton 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 

 

 Tel: +44 (0) 20 7710 7600

The information below, set out in accordance with the requirements of the EU Market Abuse Regulation, provides further detail on the grant of options to PDMRs.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 Francois Martelet

2

Reason for the notification

a)

Position/status

 CEO, NetScientific plc

b)

Initial notification/ Amendment

 Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

NetScientific plc

b)

LEI

213800N5WD46G1Y7I458

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

 

Option over Ordinary Shares

 

 ISIN for NetScientific plc Ordinary Shares: GB00B9F4MT28

 

b)

Nature of the transaction

Grant of option

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 £0.455

 300,000

 

d)

Aggregated information

- Aggregated volume

- Price

 

300,000

£0.455

e)

Date of the transaction

21 June 2018

f)

Place of the transaction

Off market

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 Ian Postlethwaite

2

Reason for the notification

a)

Position/status

 CFO, NetScientific plc

b)

Initial notification/ Amendment

 Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

NetScientific plc

b)

LEI

213800N5WD46G1Y7I458

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

 

Option over Ordinary Shares

 

 ISIN for NetScientific plc Ordinary Shares: GB00B9F4MT28

 

b)

Nature of the transaction

Grant of option

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 £0.455

 200,000

 

d)

Aggregated information

- Aggregated volume

- Price

 

200,000

£0.455

e)

Date of the transaction

21 June 2018

f)

Place of the transaction

Off market

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHMMGZVKVRGRZM
Date   Source Headline
18th Nov 20167:00 amRNSNetscientific: Vortex Biosciences Analysis Data
3rd Nov 20164:34 pmRNSVortex Gains CE Mark and FDA Class 1 Registration
26th Oct 201612:30 pmRNSVortex Biosciences Appoints Non-Executive Director
30th Sep 20167:00 amRNSProAxsis Gains CE Mark for its Respiratory Test
27th Sep 20167:00 amRNSNetScientific Interim Results
23rd Sep 20167:00 amRNSWanda Technology Selected by 24Hr HomeCare
12th Sep 20167:00 amRNSGlycotest strengthens IP portfolio
8th Sep 20167:00 amRNSWanda Appoints Digital Health Non-Exec Director
6th Sep 20167:00 amRNSNotice of Interim Results
19th Aug 20167:00 amRNSWanda Launches First Consumer App
18th Aug 20167:06 amRNSVortex Biosciences Appoints Experts to New SAB
3rd Aug 20167:00 amRNSVortex Licenses Patents From Harvard University
28th Jul 20167:00 amRNSChange of Adviser
27th Jul 20167:00 amRNSWanda Appoints Medical Director
22nd Jul 20167:00 amRNSA to Z Home Health Care selects Wanda technologies
27th Jun 20167:00 amRNSGrant of Options to Director
15th Jun 20162:13 pmRNSResult of AGM
14th Jun 20167:00 amRNSVortex Biosciences appoints Chairman of SAB
14th Jun 20167:00 amRNSNetScientific hosts Capital Markets Day
10th Jun 20167:30 amRNSConfirmed Start Date for Ian Postlethwaite as CFO
7th Jun 20167:00 amRNSPortfolio PDS Biotechnology presents at BIO 2016
23rd May 20169:00 amRNSNotice of AGM
18th Apr 20167:00 amRNSNetScientific's Vortex presents data at AACR
13th Apr 20167:00 amRNSPDS Biotechnology Reports Positive Phase 1 Results
7th Apr 20167:00 amRNSAnnual Financial Report
5th Apr 20167:00 amRNSNetscientific Appoints Ian Postlethwaite as CFO
30th Mar 20167:00 amRNSProAxsis Forms Scientific Advisory Board
24th Mar 20167:00 amRNSNotice of Results
16th Mar 20167:00 amRNSWanda Forms Scientific Advisory Board
7th Mar 20162:00 pmRNSAdoption of reduced disclosure framework
1st Mar 20161:00 pmRNSVortex co-founder receives US Presidential award
29th Feb 20167:00 amRNSWanda and Dignity Health launch OncoVerse platform
17th Feb 20167:00 amRNSNetScientific appoints Prof. Stephen Smith as NED
9th Feb 201611:05 amRNSPDS Biotechnology partners with NCI
8th Feb 20163:14 pmRNSGrant of Options to Director
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 201611:09 amRNSPDS Biotechnology adds drug development executives
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.